Dr. Davin C. Ashraf, M.D.
Ophthalmology (Ophthalmic Plastic and Reconstructive Surgery Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 171
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of California, Geffen School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmic Plastic and Reconstructive Surgery Physician primary
OR license MD205564 -
Ophthalmology Physician
OR license MD205564
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 171
- Services billed
- 474
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 64 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 57 |
| Photography of content of eyes | 29 | 28 |
| Exam of visual field with limited testing | 27 | 27 |
| Biopsy of eyelid | 14 | 14 |
| Extensive repair of turning-outward eyelid defect | 14 | 12 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 12 | 12 |
| Temporary closure of eyelids by suture | 11 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Portland, OR | 95 |
| Erythromycin (erythromycin base) Other prescribers in Portland, OR | 93 |
| Oxycodone Hcl Other prescribers in Portland, OR | 33 |
| Tepezza (teprotumumab-trbw) | 27 |
| Celecoxib Other prescribers in Portland, OR | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 15 payments worth $1,426 in total to this clinician.
| Amgen Inc. | $1,353 |
|---|---|
| DePuy Synthes Sales Inc. | $72.80 |
| Travel and Lodging | $1,353 |
|---|---|
| Food and Beverage | $72.80 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $464 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $267 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $215 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $113 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $50.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $50.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.57 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.57 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $20.41 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $464 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $267 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $215 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $113 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $50.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $50.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.57 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.57 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $48.00 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $20.41 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $14.70 |
| Amgen Inc. Jul 24, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to San Francisco, CA · in-kind | $14.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $53,560 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.